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ScienceDirectX chromosome inactivation, the transcriptional inactivation of
one X chromosome in somatic cells of female mammals, has
revealed important advances in our understanding of
development, epigenetic control, and RNA biology. Most of this
knowledge comes from extensive studies in the mouse;
however, there are some significant differences when
compared to human biology. This is especially true in
pluripotent cell types and, over the past few years, a significant
amount of work has been dedicated to understanding these
differences. This review focuses specifically on recent
advances in the mechanism of Xist spreading, the role of Xist in
cancer, the effects of reprogramming on X chromosome
inactivation in human induced pluripotent stem cells, and new
tools for studying X chromosome inactivation.
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Introduction
The field of X chromosome inactivation (XCI), the pro-
cess by which one X chromosome in female mammals is
transcriptionally inactivated in order to equalize gene
expression in males and females, is now in its sixth decade
and has produced a substantial understanding of the cell
and molecular biology underlying this epigenetic regula-
tion [1,2]. Even though our mechanistic understanding of
the events in XCI is quite sophisticated, we are still
identifying new players and further refining our under-
standing as illustrated by recent advances. With the
discovery of induced pluripotent stem cells (iPSCs) in
2006 [3], a new subfield of XCI emerged to characterize XCurrent Opinion in Genetics & Development 2014, 28:78–82 chromosome state in these cells and their derivatives.
This new technology made it possible to examine the
same cells in a somatic context as well as an embryonic-
like context to determine changes to the X chromosome
during cell fate decisions, providing tools to interrogate
reprogramming and pluripotency.
This review will address new mechanistic advances in
mouse and human XCI biology, the role of XCI in cancer
initiation and progression, and new data on X chromo-
some state following reprogramming. Finally, it will dis-
cuss a new tool that has the ability to mark XCI in
individual cells, which may be able to address many
outstanding questions in the field. These recent advances
and future discoveries in X chromosome biology are
certain to aid in the translation of cell based therapies
to the clinic (Table 1).
New mechanisms of XCI
Much of the mechanism of X chromosome inactivation
has been extensively studied and well characterized,
including understanding the role of the antisense inhibi-
tor, Tsix, to the proteins recruited to maintain the chromo-
some-wide inactivation, and the DNA–RNA–protein
interactions that maintain X inactivation [4–8]. However,
a recent breakthrough was made in understanding how
Xist is able to spread along the length of the entire
chromosome without silencing other chromosomes or
active areas of the X chromosome. Engreitz et al. using
1054 tiled probes to the 17-kb Xist transcript, pulled down
unique sequences of genomic DNA bound to Xist at five
time points during differentiation as Xist becomes
induced. After ruling out the role of sequence motifs
with Xist-recruiting ability, they found that the initial
DNA sites bound by Xist were spatially proximal (based
on Hi-C data) to the Xist locus [9]. These results support
a model that Xist spreads along the length of the chromo-
some by binding to distal sites that are spatially organized
close to the newly transcribed Xist RNA. By being able to
modify chromatin structure at these regions, Xist is able to
spread to newly silenced regions of the genome. Further-
more, regions that escape XCI are able to loop out and
remain active while still permitting spatial spread of
Xist. Since much more of the genome escapes XCI in
humans compared to mouse, it will be interesting to
determine if this mechanism is conserved in humans.
Other work has identified a new long non-coding RNA,
XACT, specifically in human pluripotent stem cells [10].
While not expressed in mice, XACT coats the active Xwww.sciencedirect.com
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Table 1
Understanding mechanisms of X chromosome inactivation can
improve all aspects of developing clinical therapies.
Reprogramming Controlling XCI during reprogramming will allow
specific X chromosome states to be achieved
in resulting iPSCs.
Dual color reporter system may be able to
elucidate the timing of reactivation at a fine
tuned resolution.
iPSCs Discoveries, such as XACT, show how unique
human pluripotent biology is compared to mouse
and suggest new ways to control XCI.
Differentiation Maintaining XCI during differentiation will be
crucial to limit the presence of potentially
oncogenic cells.
Somatic cells The more we uncover about different states of
XCI in human cells, the better we will be able
to determine if in vitro cells are replicating the
biology of in vivo cells.
Transplantation Monitoring how XCI state changes over long
periods of time as well as changes that may
occur in vivo will be necessary to ensure cells
maintain the desired state.chromosome and, in the absence of XIST, coats both
chromosomes. Perhaps this reflects a human-specific
mechanism by which cells prevent silencing of both X
chromosome, instead of, as in mouse, using TSIX as an
antisense repressor. It is known that the human TSIX
RNA has significantly less complementarity to human
XIST than mouse Tsix and Xist, and its ability to act as an
effective suppressor in this way has been questioned
[11,12]. This paper begins to shed light on human specific
aspects of XCI that may underlie the mechanistic differ-
ences between mouse and human.
Finally, two other studies provide additional pieces of the
mechanistic puzzle. First is evidence for the role of Jarid2
in recruiting PRC2 to Xist RNA in helping to mediate
inactivation [13]. The second is the surprising finding
that the first intron of Xist seems dispensable for Xist
expression and normal function during XCI in stem cells
and during development, despite the fact that the region
exhibits strong pluripotency factor binding [14]. Taken
together these mechanistic results illustrate that there is
still much to learn about XCI in both humans and mice.
XCI and cancer
The role of the X chromosome in cancer has been well
documented but much data is only correlational [15–18].
Recent papers provide genetic and developmental evi-
dence that X chromosome changes in somatic cells can
cause cancer. Using human breast cancer as a model,
researchers found that half of the sporadic basal-like
cancers were characterized by duplication of the active
X chromosome and loss of the inactive X chromosome
[19]. While these abnormalities did not contribute to
global increases of gene expression from the X chromo-
some, it was associated with overexpression of a subset ofwww.sciencedirect.com genes. In addition, another paper provided evidence that
the inactive X chromosomes accumulates more mutations
than any other autosome in cancer genomes compared to
non-tumorigenic samples [20], suggesting an inability to
successfully repair damage. If this inactive X chromosome
later becomes active, it could further contribute to genetic
mutation load during cancer progression.
An elegant and convincing study in mouse showed direct
evidence that Xist loss causes cancer. Researchers con-
ditionally knocked out Xist in vivo in mouse hematopoie-
tic stem cells after random X chromosome inactivation
had already taken place. A female specific, fully pene-
trant, lethal blood cancer developed that began killing
mice at 1.5 months. After two years, only 10 percent of the
mice were still alive and neither homozygous nor hetero-
zygous female mice have escaped the lethal phenotype at
the time the research was published [21]. While this was
only demonstrated in one lineage in the mouse, other data
suggest that the loss of XIST in human iPSCs is strongly
correlated with increased expression of X-linked onco-
genes [22]. Interestingly, male iPSCs, compared to
female iPSCs, are more homogeneous and do not over-
express these genes suggesting a potential increased risk
of tumorigenesis in female stem cells. This is a major
hurdle in the clinical translation of female stem cells and
will require much more work to understand the different
potentials of stem cells with different XCI states
(Table 1).
Reprogramming and XCI state
Early mouse studies have revealed simple binaries: plur-
ipotent cell types have two active X chromosomes (XaXa)
(extensively reviewed in [2,23]), and somatic cell types
have one active and one inactive X chromosome (XaXi)
[24]. Differentiation of a mouse pluripotent cell into a
somatic cell results in the inactivation of one X chromo-
some [25]. This is true for both embryonic stem (ES) cells
and iPSCs in the mouse with the exception of ES cells
derived from the epiblast. Epiblast stem cells (EpiSC) are
thought to represent a distinct state of pluripotency, as
they cannot contribute to blastocyst chimeras, have vari-
able differentiation bias, and are characterized by an
inactive X chromosome [26,27]. However, they can be
converted to ES, reactivating the inactive X chromosome
in the process [28]. These relationships in mouse have not
directly translated to human biology. There is no uni-
versal rule governing the X chromosome state in human
pluripotent cell types; indeed, a range of states are com-
mon (Figure 1). While these differences could be species
specific, they may be due to differences in pluripotent
state as human ES and mouse EpiSC are similar culture
conditions and gene expression and the inactivation of an
X chromosome [26,27].
In addition to examining human ES cells, several groups
have analyzed iPSCs for X chromosome state and haveCurrent Opinion in Genetics & Development 2014, 28:78–82
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Three classes of X chromosome states exist in human pluripotent cells. Three classes of X chromosome state have been shown to exist in human
stem cells. The first represents cells with two active X chromosomes which can be achieved by changes in culturing conditions by
reprogramming, which occasionally produces cells with two active X chromosomes. The second class of stem cell has an inactive X chromosome,
which can also be induced by culturing conditions or due to differentiation. Finally, as many people have shown, XaXi cells can result from the
reprogramming process itself. The third class is characterized by partial XCI in that XIST is not present but much of the chromosome is still
inactivated. Over time, more transcripts across the entire X chromosome can become expressed, known as erosion, and this phenomenon is
known to be the result of continued passaging. Questions about the relationship of these three classes still exist. It is unclear whether
differentiation can rescue a partially inactivated X chromosome to a fully inactivated one. Additionally it has not been shown whether extensive
passaging could render a previously inactivated X chromosome completely reactivated.generated seemingly conflicting results. Some groups
report reactivation of the X chromosome in iPSCs (XaXa)
[31–33] while others show that the X chromosome
remains inactive (XaXi) [29,34]. Interestingly, there are
reports on the variability in XCI (same reprogramming
method leading to multiple states; single clone containing
cells of different states) suggesting that the variability is
biologically, not methodologically, based [33,35]. These
differences again raise questions about the suitability of
these cell and their byproducts in clinical settings and
suggests a need for careful characterization of these cells
and their properties (Figure 1).
In spite of these advances, studies have not yet docu-
mented an ability to control the X chromosome state in
cells, especially iPSCs. However, recent work in this area
has provided some exciting insights. A group let by
Shinya Yamanaka was able to change culture conditions
to affect the outcome of reprogramming. By culturing
fibroblasts on SNL feeders, which produce high levels of
leukemia inhibitory factor, Tomoda et al. were able to
produced human iPSCs that were characterized by X
chromosome reactivation [36]. Human iPSCs produced
in this manner reactivated XIST upon differentiation and
iPSCs derived under other conditions and subsequently
moved to SNL feeders could be coaxed to reactivate the
inactive X chromosome. Interestingly, the SNL feeders
provide additional factors other than increased LIF, as
rLIF alone only caused biallelic expression of a subset of
X chromosome genes compared to those cells grown onCurrent Opinion in Genetics & Development 2014, 28:78–82 the SNL feeders. Supporting their work, many other
groups have reported the effects of culture conditions
on ES cell XCI state suggesting that different conditions
could also control XCI in iPSCs [30,37,38]. This system
provides an exciting opportunity to understand the
human biology of XCI changes as a proportion of cells
can be forced to switch between XaXa and XaXi states.
Taken together, it is important to determine what con-
stitutes an ideal state of human pluripotent cells, but it is
not as easy as deciding on two active X chromosomes or
one. How these states are reached is also important: some
human iPSCs with two active X chromosomes are due to
erosion of XCI and have poor differentiation ability [29],
while pluripotent cells can also be converted under
defined conditions to replicate the pluripotency state
found in mouse ES cells including a reactivated X
chromosome [30]. While XaXa cells are the gold standard
in mouse, perhaps cells with two active X chromosomes
represent an epigenetic abnormality rather than the ideal
state for in human pluripotency. These data suggest that
different mechanisms may be involved and perhaps one is
preferable to another in generating the ideal state.
Simple tools provide big possibilities
New tools have been developed recently that have aided
our understanding of the mechanisms of XCI, especially,
as mentioned before, new methods to identify DNA
bound to RNA. However a recent paper took a simple
approach that is likely to answer fundamental questionswww.sciencedirect.com
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sufficiently studied. Wu et al. developed a dual color
mouse line by integrating Cre-inducible, fluorescent
proteins into the Hprt1 locus, a locus known to obey
XCI, on both X chromosomes [39]. Using this elegant
system, they were able to generate mice in which every
single cell was labeled either green or red, reflecting
which X chromosome remained active in a given cell.
They were able to generate maps of XCI in all the tissues
of the body, down to single cell resolution.
This valuable tool opens a number of interesting areas of
follow up. While X chromosome reactivation during
reprogramming is well known, the precise timing of these
events are difficult to study due to the small fraction of
cells that eventually become reprogrammed. Using cell
lines derived from these mice, one could determine the
precise timing of reactivation of the X chromosome in
relation to obvious morphological changes or presence of
gene expression profile changes. Female germ cell differ-
entiation from stem cells could also benefit from this
technology, as they are the only in vivo cell type with two
active X chromosomes. This type of tool would be extre-
mely useful in a human cell line, where XCI is more
variable and less well understood. In the context of
reprogramming, it would likely reveal important under-
standing of the relationship between the three XCI states
that exist in human iPSCs (XaXa, XaXi, XaXi*, see
Figure 1).
Conclusions: moving toward the clinic
Even after 50 years, the field of XCI is still providing new
insights as highlighted by the recent finding of XACT in
human pluripotent cells. As technologies become more
sophisticated and we are better able to profile single cells,
we are sure to understand even more about X chromo-
some biology. As the field moves forward, there are a
number of unanswered questions that remain, especially
in the human system. Specifically, how will we utilize our
knowledge of XCI to impact the future clinical use of
stem cells?
Since XCI is a uniquely female biology, it is an important
area of study to ensure that patient-specific therapies
enter the clinic at similar rates for men and women. As
such, there are a number of areas that need to be
addressed. First, how do we direct XCI in cell types of
interest and how can we ensure that the X chromosome
remains inactive? While the mouse has provided incred-
ible insight, many of these studies will need to be con-
ducted in human cell lines to address the human-specific
differences. Additionally, what are the in vivo con-
sequences of changes in XCI? We know that the mouse
hematopoietic system undergoes drastic changes [21];
are these changes more broadly applicable? Are they
relevant in human biology? Initial findings suggest a
possible link to cancer in human iPSCs but more workwww.sciencedirect.com is surely needed [22]. The X chromosome is full of
surprises and if the future of the field is anything like the
last few years, it would seem we have much to look
forward to.
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